Voyager Therapeutics And REGENXBIO Announce Exercise Of Options For Rights To NAV Vectors

CAMBRIDGE, Mass., and ROCKVILLE, Md., Nov. 29, 2016 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system (CNS), and REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy based on its proprietary NAV® Technology Platform (NAV), today announced that Voyager has exercised commercial options for the use of REGENXBIO's NAV vectors for the development and commercialization of gene therapies for specific neurological diseases.

Upon exercise of the options, REGENXBIO has granted Voyager a non-exclusive worldwide commercial license, with rights to sublicense, to three specific NAV vector sequences covered by REGENXBIO's NAV Technology Platform, each for the treatment of a specific neurological disease.  In return for these rights, REGENXBIO will receive undisclosed upfront payments, ongoing fees, milestone payments and royalties on net sales of products incorporating the licensed intellectual property.

"Today's announcement aligns with our stated goal of advancing our multiple preclinical programs during this year and into 2017 towards selection of lead clinical candidates," said Steven Paul, M.D., President and Chief Executive Officer of Voyager Therapeutics.  "Exercising the commercial options with REGENXBIO represents an important step for our preclinical pipeline programs, and we are excited with the progress of our continued collaboration with REGENXBIO."

"These option exercises serve as further validation of our proprietary NAV Technology Platform, the breadth of our intellectual property portfolio, and the unique properties of NAV vectors for targeting the central nervous system and a number of other organ systems," said Kenneth T. Mills, President and Chief Executive Officer of REGENXBIO.  "As a leader in next-generation AAV gene therapy, REGENXBIO is pleased to continue our collaboration with Voyager and its pursuit of developing and delivering life-changing treatments for severe diseases of the CNS."

If you liked this article you might like

Voyager Gene Therapy Shows Early, Promising Motor Function Improvements for Parkinson's Patients